Effect of oxytocin on the behavioral activity in the behavioral despair depression rat model

Neuropeptides

Volumn 48, Issue 2, 2014, Pages 83-89

  Yan, Yuan ^a   Wang, Yong Liang ^a   Su, Zhou ^a   Zhang, Yi ^a   Guo, Shuang Xi ^a   Liu, Ai Juan ^a   Wang, Chang Hong ^b   Sun, Fang Jie ^c   Yang, Jun ^c,d  

^a The First Affiliated Hospital of Xinxiang Medical University   (China)

^b Henan Provincial Mental Hospital   (China)

^c Xinxiang Institute for New Medicine   (China)

^d Henan Fenghuang Pharmaceutical Co Ltd   (China)

Author keywords

Behavioral despair; Brain; Depression; Oxytocin; Periphery

Indexed keywords

OXYTOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; BRAIN; CONTROLLED STUDY; DEPRESSION; FORCED SWIM TEST; HOPELESSNESS; IMMOBILITY; NONHUMAN; PRIORITY JOURNAL; RAT; TAIL SUSPENSION TEST; ANIMAL; ANIMAL BEHAVIOR; BLOOD; CENTRAL NERVOUS SYSTEM; DISEASE MODEL; DRUG EFFECTS; IMMOBILIZATION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; PHYSIOLOGY; SECRETION (PROCESS); SPRAGUE DAWLEY RAT; SWIMMING;

ANIMALIA; RATTUS;

ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM; DEPRESSION; DISEASE MODELS, ANIMAL; HINDLIMB SUSPENSION; INJECTIONS, INTRAVENOUS; INJECTIONS, INTRAVENTRICULAR; MALE; OXYTOCIN; RATS, SPRAGUE-DAWLEY; SWIMMING;

EID: 84896549717     PISSN: 01434179     EISSN: 15322785     Source Type: Journal    
DOI: 10.1016/j.npep.2014.01.001     Document Type: Article

References (50)

1. Amico J.A., Mantella R.C., Vollmer R.R., Li X. Anxiety and stress responses in female oxytocin deficient mice. J. Neuroendocrinol. 2004, 16:319-324.
2. Anderberg U.M., Uvnas-Moberg K. Plasma oxytocin levels in female fibromyalgia syndrome patients. Z. Rheumatol. 2000, 59:373-379.
3. Arletti R., Bertolini A. Oxytocin acts as an antidepressant in two animal models of depression. Life Sci. 1987, 41:1725-1730.
4. Bunck M., Czibere L., Horvath C., Graf C., Frank E., Kessler M.S., Murgatroyd C., Müller-Myhsok B., Gonik M., Weber P., Pütz B., Muigg P., Panhuysen M., Singewald N., Bettecken T., Deussing J.M., Holsboer F., Spengler D., Landgraf R. A hypomorphic vasopressin allele prevents anxiety-related behavior. PLoS One 2009, 4:e5129.
5. Cardoso C., Ellenbogen M.A., Linnen A.M. Acute intranasal oxytocin improves positive self-perceptions of personality. Psychopharmacology 2012, 220:741-749.
6. Chaviaras S., Mak P., Ralph D., Krishnan L., Broadbear J.H. Assessing the antidepressant-like effects of carbetocin, an oxytocin agonist, using a modification of the forced swimming test. Psychopharmacology 2010, 210:35-43.
7. Cryan J.F., Valentino R.J., Lucki I. Assessing substrates underlying the behavioral effects of antidepressants using the modified rat forced swimming test. Neurosci. Biobehav. Rev. 2005, 29:547-569.
8. Cyranowski J.M., Hofkens T.L., Frank E., Seltman H., Cai H.M., Amico J.A. Evidence of dysregulated peripheral oxytocin release among depressed women. Psychosom. Med. 2008, 70:967-975.
9. Dubrovsky B., Harris J., Gijsbers K., Tatarinov A. Oxytocin induces long-term depression on the rat dentate gyrus: possible ATPase and ectoprotein kinase mediation. Brain Res. Bull. 2002, 58:141-147.
10. Elands J., Barberis C., Jard S., Tribollet E., Dreifuss J.J., Bankowski K., Manning M., Sawyer W.H. 125I-labelled d(CH2)5[Tyr(Me)2, Thr4, Tyr-NH2(9)]OVT: a selective oxytocin receptor ligand. Eur. J. Pharmacol. 1988, 147:197-207.
11. Gimpl G., Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol. Rev. 2001, 81:629-683.
12. Grippo A.J., Wu K.D., Hassan I., Carter C.S. Social isolation in prairie voles induces behaviors relevant to negative affect: toward the development of a rodent modent model focused on co-occurring depression and anxiety. Depress. Anxiety 2008, 25:E17-E26.
13. Landgraf R., Neumann I.D. Vasopressin and oxytocin release within the brain: a dynamic concept of multiple and variable modes of neuropeptide communication. Front. Neuroendocrinol. 2004, 25:150-176.
14. Lim M.M., Young L.J. Neuropeptidergic regulation of affiliative behavior and social bonding in animals. Horm. Behav. 2006, 50:506-517.
15. Maggi M., Malozowski S., Kassis S., Guardabasso V., Rodbard D. Identification and characterization of two classes of receptors for oxytocin and vasopressin in porcine tunica albuginea, epididymis, and vas deferens. Endocrinology 1987, 120:986-994.
16. Matsushita H., Matsuzaki M., Han X.J., Nishiki T., Ohmori I., Michiue H., Matsui H., Tomizawa K. Antidepressant-like effect of sildenafil through oxytocin-dependent cyclic AMP response element-binding protein phosphorylation. Neuroscience 2012, 200:13-18.
17. Matsushita H., Tomizawa K., Okimoto N., Nishiki T., Ohmori I., Matsui H. Oxytocin mediates the antidepressant effects of mating behavior in male mice. Neurosci. Res. 2010, 68:151-153.
18. Matsuzaki M., Matsushita H., Tomizawa K., Matsui H. Oxytocin: a therapeutic target for mental disorders. J. Physiol. Sci. 2012, 62:441-444.
19. McEwen B.B. The Role of Vasopressin and Oxytocin in Memory Processing 2004, vol. 50. Elsevier Science, Amsterdam.
20. Meyer S.E., Chrousos G.P., Gold P.W. Major depression and the stress system: a life span perspective. Dev. Psychopathol. 2001, 13:565-580.
21. Meynen G., Unmehopa U.A., Hofman M.A., Swaab D.F., Hoogendijk W.J. Hypothalamic oxytocin mRNA expression and melancholic depression. Mol. Psychiatry 2007, 12:118-119.
22. Ohlsson B., Truedsson M., Bengtsson M., Torstenson R., Sjölund K., Björnsson E.S., Simrèn M. Effects of long-term treatment with oxytocin in chronic constipation; a double blind, placebo-controlled pilot trial. Neurogastroenterol. Motil. 2005, 17:697-704.
23. Onaka T. Neural pathways controlling central and peripheral oxytocin release during stress. J. Neuroendocrinol. 2004, 16:308-312.
24. Ozsoy S., Esel E., Kula M. Serum oxytocin levels in patients with depression and the effect of gender and antidepressant treatment. Psychiatry Res. 2009, 169:249-252.
25. Parker K.J., Buckmaster C.L., Schatzberg A.F., Lyons D.M. Intranasal oxytocin administration attenuates the ACTH stress response in monkeys. Psychoneuroendocrinology 2005, 30:924-929.
26. Parker K.J., Kenna H.A., Zeitzer J.M., Keller J., Blasey C.M., Amico J.A., Schatzberg A.F. Preliminary evidence that plasma oxytocin levels are elevated in major depression. Psychiatry Res. 2010, 178:359-362.
27. Parker K.J., Schatzberg A.F., Lyons D.M. Neuroendocrine aspects of hypercortisolism in major depression. Horm. Behav. 2003, 43:60-66.
28. Pedersen C.A., Caldwell J.D., Peterson G., Walker C.H., Mason G.A. Oxytocin activation of maternal behavior in the rat. Ann. N.Y. Acad. Sci. 1992, 652:58-69.
29. Pellegrino K.J., Pellegrino A.S., Cushman A.J. An Atereotaxic Atlas of the Brain 1979, Plenum, New York.
30. Petit-Demouliere B., Chenu F., Bourin M. Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology 2005, 177:245-255.
31. Porsolt R.D., Bertin A., Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch. Int. Pharmacodyn. Ther. 1977, 229:327-336.
32. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
33. Purba J.S., Hoogendijk W.J., Hofman M.A., Swaab D.F. Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch. Gen. Psychiatry 1996, 53:137-143.
34. Ring R.H., Schechter L.E., Leonard S.K., Dwyer J.M., Platt B.J., Graf R., Grauer S., Pulicicchio C., Resnick L., Rahman Z., Sukoff Rizzo S.J., Luo B., Beyer C.E., Logue S.F., Marquis K.L., Hughes Z.A., Rosenzweig-Lipson S. Receptor and behavioral pharmacology of WAY-267464, a non-peptide oxytocin receptor agonist. Neuropharmacology 2010, 58:69-77.
35. Scantamburlo G., Ansseau M., Geenen V., Legros J.J. Intranasal oxytocin as an adjunct to escitalopram in major depression. J. Neuropsychiatry Clin. Neurosci. 2011, 23:E5.
36. Scantamburlo G., Hansenne M., Fuchs S., Pitchot W., Marechal P., Pequeux C., Ansseau M., Legros J.J. Plasma oxytocin levels and anxiety in patients with major depression. Psychoneuroendocrinology 2007, 32:407-410.
37. Schelling P., Meyer D., Loos H.E., Speck G., Phillips M.I., Johnson A.K., Ganten D. A micromethod for measurement of rennin in brain nuclei: its application in spontaneously hypertensive rats. Neuropharmacology 1982, 21:455-463.
38. Slattery D.A., Neumann I.D. Oxytocin and major depressive disorder: experimental and clinical evidence for links to aetiology and possible treatment. Pharmaceuticals 2010, 3:702-724.
39. Steru L., Chemat R., Thierry B., Simon P. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 1985, 85:367-370.
40. Swedo S.E., Leonard H.L., Kruesi M.J., Rettew D.C., Listwak S.J., Berrettini W., Stipetic M., Hamburger S., Gold P.W., Potter W.Z., Rapoport J.L. Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. Arch. Gen. Psychiatry 1992, 49:29-36.
41. Windle R.J., Kershaw Y.M., Shanks N., Wood S.A., Lightman S.L., Ingram C.D. Oxytocin attenuates stress-induced c-fos mRNA expression in specific forebrain regions associated with modulation of hypothalamo-pituitary-adrenal activity. J. Neurosci. 2004, 24:2974-2982.
42. Witt D.M., Winslow J.T., Insel T.R. Enhanced social interactions in rats following chronic, centrally infused oxytocin. Pharmacol. Biochem. Behav. 1992, 43:855-861.
43. Yan H.C., Cao X., Das M., Zhu X.H., Gao T.M. Behavioral animal models of depression. Neurosci. Bull. 2010, 26:327-337.
44. Yang J., Li P., Liang J.Y., Pan Y.J., Yan X.Q., Yan F.L., Hao F., Zhang X.Y., Qiu P.Y., Wang D.X. Oxytocin in the periaqueductal gray regulates nociception in the rats. Regul. Pept. 2011, 169:39-42.
45. Yang J., Liang J.Y., Li P., Pan Y.J., Qiu P.Y., Zhang J., Hao F., Wang D.X. Oxytocin in the periaqueductal gray participates in pain modulation in the rat by influencing the endogenous opiate peptides. Peptides 2011, 32:1255-1261.
46. Yang J., Liang J.Y., Zhang X.Y., Qiu P.Y., Pang Y.J., Li P., Zhang J., Hao F., Wang D.X., Yan F.L. Oxytocin, but not arginine vasopressin is involving in the antinociceptive role of hypothalamic suproptic nucleus. Peptides 2011, 32:1042-1046.
47. Yang J., Pan Y.J., Zhao Y., Qiu P.Y., Lu L., Li P., Chen F., Yan X.Q., Wang D.X. Oxytocin in the rat caudate nucleus influences pain modulation. Peptides 2011, 32:2104-2107.
48. Yang J., Yang Y., Chen J.M., Liu W.Y., Wang C.H., Lin B.C. Effect of oxytocin on acupuncture analgesia in the rat. Neuropeptides 2007, 41:285-292.
49. Yang J., Yang Y., Chen J.M., Liu W.Y., Wang C.H., Lin B.C. Central oxytocin enhances antinociception in the rat. Peptides 2007, 28:1113-1119.
50. Zhou X.J., Yang J., Yan F.L., Wang D.X., Liu W.Y., Li X.Y., Fan X.Q., Hao F., Yan X.Q., Li X.P., Li H., Lin B.C. Norepinephrine plays an important role in antinociceptive modulation of hypothalamic paraventricular nucleus in the rat. Int. J. Neurosci. 2010, 120:428-438.